Scarica l'app Stockscreener
5.80
13.28%
0.68
Precedente Chiudi:
$5.12
Aprire:
$5.15
Volume 24 ore:
20,120
Relative Volume:
1.34
Capitalizzazione di mercato:
$6.64M
Reddito:
-
Utile/perdita netta:
$-17.27M
Rapporto P/E:
-0.5597
EPS:
-10.3626
Flusso di cassa netto:
$-10.59M
1 W Prestazione:
+51.44%
1M Prestazione:
-32.87%
6M Prestazione:
-81.87%
1 anno Prestazione:
-87.97%
Intervallo 1D:
$5.0826
$6.00
Intervallo di 1 settimana:
$3.78
$6.00
Portata 52W:
$3.25
$63.20
Akari Therapeutics Plc Adr Stock (AKTX) Company Profile
Nome
Akari Therapeutics Plc Adr
Settore
Industria
Telefono
(929) 274-7510
Indirizzo
401 EAST JACKSON STREET, TAMPA
Compare AKTX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AKTX
Akari Therapeutics Plc Adr
|
5.80 | 5.86M | 0 | -17.27M | -10.59M | -10.36 |
VRTX
Vertex Pharmaceuticals Inc
|
441.20 | 110.81B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
750.57 | 78.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
849.04 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
309.66 | 42.71B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
323.87 | 35.60B | 5.36B | 287.73M | 924.18M | 2.5229 |
Akari Therapeutics Plc Adr Stock (AKTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-08 | Downgrade | Maxim Group | Buy → Hold |
| 2026-01-05 | Iniziato | Ladenburg Thalmann | Buy |
| 2025-07-18 | Iniziato | Maxim Group | Buy |
| 2019-01-04 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-02-08 | Iniziato | B. Riley FBR, Inc. | Neutral |
| 2017-09-22 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2017-05-31 | Aggiornamento | Chardan Capital Markets | Sell → Neutral |
| 2017-04-17 | Reiterato | Chardan Capital Markets | Sell |
| 2016-07-11 | Iniziato | Chardan Capital Markets | Sell |
Mostra tutto
Akari Therapeutics Plc Adr Borsa (AKTX) Ultime notizie
Akari Therapeutics (NASDAQ: AKTX) registers 867,023 ADSs after ADS ratio change - Stock Titan
Akari Therapeutics PLC (FRA:CLA1) Stock Price, Trades & News - GuruFocus
Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC - Sahm
Total equity of Akari Therapeutics Plc Sponsored ADR – LSX:A4270Y - TradingView — Track All Markets
Long term debt to total assets ratio of Akari Therapeutics Plc Sponsored ADR – FWB:CLA1 - TradingView
Discontinued operations of Akari Therapeutics Plc Sponsored ADR – MUN:CLA1 - TradingView
Akari Therapeutics partners with WuXi XDC on ADC development By Investing.com - Investing.com India
Akari Therapeutics partners with WuXi XDC on ADC development - Investing.com
Who's Buying or Selling Akari Therapeutics PLC (FRA:CLA1) Stock Today? - GuruFocus
Akari Therapeutics PLC (FRA:CLA1) Dividend - GuruFocus
Akari Therapeutics PLC (FRA:CLA1)Valuation Measures & Financial Statistics - GuruFocus
Akari Therapeutics PLC Stock Baskets | FRA:CLA1 - GuruFocus
Akari Therapeutics PLC Stock Operating Data - GuruFocus
Akari Therapeutics PLC (FRA:CLA1) Stock News, Headlines & Updates - GuruFocus
Akari Therapeutics PLC (FRA:CLA1) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Akari Therapeutics PLC (STU:CLA1) Stock News, Headlines & Updates - GuruFocus
Akari Therapeutics PLC (STU:CLA1) Valuation - GuruFocus
Akari Therapeutics PLC (STU:CLA1) Dividend - GuruFocus
Akari Therapeutics PLC Stock Baskets | STU:CLA1 - GuruFocus
Akari Therapeutics PLC (STU:CLA1)Valuation Measures & Financial Statistics - GuruFocus
Akari Therapeutics ADR: Dividend historical data and projections - marketscreener.com
Akari Therapeutics ADR: Revenue and Earnings Analysts Forecasts Revisions | AKTX | US00972G4055 - MarketScreener
Akari Therapeutics (NASDAQ: AKTX) sets ADS ratio to 1:80,000 in F-6/A filing - Stock Titan
Akari Therapeutics, Plc Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Akari Therapeutics (NASDAQ: AKTX) outlines ADC oncology strategy - Stock Titan
Short Interest in Akari Therapeutics PLC (NASDAQ:AKTX) Declines By 19.4% - Defense World
Akari Therapeutics revises ADS ratio to maintain Nasdaq compliance - MSN
Get insights into the top gainers and losers of Thursday's after-hours session. - ChartMill
Let's uncover which stocks are experiencing notable gaps during today's session. - ChartMill
Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026 - ChartMill
Akari Therapeutics adjusts ADS ratio to meet Nasdaq rules By Investing.com - Investing.com India
Akari Therapeutics adjusts ADS ratio to meet Nasdaq rules - Investing.com South Africa
Stay updated with the stocks that are on the move in today's after-hours session. - ChartMill
Akari Therapeutics (NASDAQ: AKTX) plans 1-for-40 ADS ratio change to meet Nasdaq bid rules - Stock Titan
Director Neal James acquires Akari (AKTX) ADS warrants via placement and note swap - Stock Titan
Akari Therapeutics marks one year under CEO Gaslightwala By Investing.com - Investing.com India
Akari Therapeutics marks one year under CEO Gaslightwala - Investing.com
Akari Therapeutics (AKTX) investors approve multiple warrant exercisability resolutions - Stock Titan
Akari Therapeutics adds Dana-Farber expert to advisory board - Investing.com
Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board - Finviz
Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board - ChartMill
Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference - Sahm
Will Akari Therapeutics Plc Depositary Receipt outperform the market in YEAR2025 Earnings Impact & Free High Return Stock Watch Alerts - mfd.ru
Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company’s Expanded ADC Pipeline - ChartMill
Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - Sahm
Akari Therapeutics (NASDAQ: AKTX) seeks approval for major warrant exercises - Stock Titan
Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors - Sahm
Curious about the stocks that are showing activity after the closing bell on Monday? - Chartmill
Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026 - GlobeNewswire Inc.
Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026 - Sahm
Akari Therapeutics to Present at the 2026 Biotech Showcase - Sahm
Akari Therapeutics Plc Adr Azioni (AKTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Akari Therapeutics Plc Adr Azioni (AKTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Gaslightwala Abizer | CEO |
Aug 22 '25 |
Buy |
0.93 |
8,000 |
7,440 |
295,574 |
| Gaslightwala Abizer | CEO |
Aug 25 '25 |
Buy |
0.90 |
3,000 |
2,700 |
298,574 |
| Gaslightwala Abizer | President & CEO |
Jun 24 '25 |
Buy |
1.16 |
5,203 |
6,035 |
277,574 |
| Gaslightwala Abizer | President & CEO |
Jun 23 '25 |
Buy |
1.15 |
943 |
1,084 |
272,371 |
| Gaslightwala Abizer | President & CEO |
Jun 20 '25 |
Buy |
1.20 |
10,000 |
12,000 |
271,428 |
| Gaslightwala Abizer | President & CEO |
Jun 17 '25 |
Buy |
1.20 |
15,000 |
18,000 |
261,428 |
2.19%
0.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):